Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
sábado, noviembre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Carlsmed Inc
CARL
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$17.42
0.20
1.16%
al cierre: Nov 20, 4:00 PM EST
$16.89
-0.53
-3.07%
After hour: 9:11 AM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Carlsmed Financials
Carlsmed (CARL) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results
Carlsmed beats Q3 estimates, raises FY2026 sales guidance to $78M-$80M, and shares jump 19.5% as analysts lift price targets.
Avi Kapoor
PRO
UPDATE: Carlsmed Q3 Adj. EPS $(0.34) Beats $(0.40) Estimate, Sales $21.554M Beat $19.154M Estimate
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 15 percent increase over losses of $(0.40) per share from the same
Benzinga Newsdesk
PRO
Carlsmed Q3 EPS $(0.45) Misses $(0.40) Estimate, Sales $21.554M Beat $19.154M Estimate
Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.40) by 12.5 percent. This is a 12.5 percent decrease over losses of $(0.40) per share from the
Benzinga Newsdesk
PRO
Carlsmed Raises FY2026 Sales Guidance from $74.000M-$78.000M to $78.000M-$80.000M vs $76.944M Est
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $74.000 million-$78.000 million to $78.000 million-$80.000 million vs $76.944 million estimate.
Benzinga Newsdesk
PRO
Carlsmed Affirms FY2026 Sales Guidance of $74.000M-$78.000M vs $74.830M Est
Carlsmed (NASDAQ:CARL) affirms FY2026 sales outlook from $74.000 million-$78.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
Benzinga Newsdesk
PRO
Carlsmed Appoints Richard Heppenstall CFO, Succeeding Leo Greenstein; Co. Reiterates FY26 Revenue Range Of $74M - $78M
Carlsmed, Inc. (Nasdaq: CARL) ("Carlsmed" or the "Company"), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that Richard Heppenstall has been
Benzinga Newsdesk